Who are we
Magellan is a private Australian company with expertise in research, development and manufacturing of stem cells for the treatment of osteoarthritis.
We lead the way globally in scientific, clinical and commercial expertise for stem cell supply and development, for both autologous treatments which use the patient’s own cells, and allogeneic treatments which use selected donor cells. We have over ten years of stem cell commercial manufacturing expertise and have cultured more than 300 billion stem cells during this time.
Our vision is to improve and enrich the lives of people currently struggling with osteoarthritis across the globe, by significantly reducing pain and improving their mobility.
Our product, MAG200 will be an off-the-shelf product to reduce pain in people whose joints are affected by Osteoarthritis, potentially eliminating the need for joint replacement surgery.
Quick Facts
100M+ people in developed world (>500M globally) have OA
OA affects 20% of the population 45+ years old, and 80% of population 65+ yrs old
Limited short term pain improvement
No disease modification
Potential risk of significant side effects
Osteoarthritis is pharmaceutical therapeutics market growing rapidly
Projected $7.3B+ USD per annum (2020) to $11B+ USD per annum by 2025
More than 1% per annum of GDP in developed nations
The average non-surgical medical cost per patient $5.9k USD per annum
Phase III for Clinical Efficacy Trial – commencing Q4 2023
OA is the Number 1 National Health Priority (by value)
Suitable for accelerated regulatory pathways including Priority Review (TGA#)
Magellan Stem Cells product MAG200 to date
Pre-clinical research
Phase I & II for Clinical Safety and primary efficacy
Phase III for Clinical Efficacy Trial – starting end 2023
Our product MAG200 has successfully completed Phase I/II of a clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence 2023.
Magellan Stem cells has secured a laboratory in southeast Melbourne and will shortly commence construction of a good manufacturing practice laboratory with the aim to complete by second quarter of 2023 and to apply for accreditation of GMP lab with the TGA soon after.
Our leading peer reviewed research and development has led to a world first publication using autologous (patient’s own) stem cell therapy in the successful management of Osteoarthritis. We are now undertaking the largest registered clinical trial with adipose derived mesenchymal stem cells therapy for Osteoarthritis in the world.
Directors and management team
Magellan Stem Cells has secured a laboratory in southeast Melbourne and will shortly commence construction of a good manufacturing practice laboratory with the aim to complete by fourth quarter of 2023.
Board of Directors
Lou Panaccio
Non-Executive Chairman
Mr Panaccio is a Chartered Accountant with a wealth of executive management experience in business and healthcare services. Mr Panaccio has been the Chief Executive Officer of Monash IVF and Executive Director of Melbourne Pathology. He was also a Non-executive Director of ASX-listed Genera Biosystems Limited.
Mr Panaccio currently holds positions on the boards of ASX and NASDAQ listed Avita Therapeutics Inc. ASX50 company Sonic Healthcare Limited, ASX-listed Rhythm Non-executive Director.
Peter Hansen
Ross Williams
Michael Kenihan
Julien Freitag
Management Team
Kiran Shah
Julien Freitag
Richard Price
